Antibodies continue to dominate biopharmaceutical approvals, but new nucleic acid modalities and cellular therapies are also slowly launching on the market. This article provides an update on three previous surveys of biopharmaceutical approvals1–3.

Fonte: VOLUME 36 NUMBER 12 DECEMBER 2018 NATURE BIOTECHNOLOGY

Para acessar a publicação na íntegra clique aqui